Below please find a link to SD Torrey Hills Capitals’ interview with AzurRx CEO James Sapirstein on April 21, 2020.
AzurRx BioPharma In the Age of COVID-19: Q&A with CEO James Sapirstein – Taking MS1819 Through the Clinic: Next Generation Therapy for Exocrine Pancreatic Insufficiency (EPI) - $2B+ Addressable Market
SD Torrey Hills Capital is not associated with AzurRx BioPharma, nor was SD Torrey Hills Capital paid for this video interview. AzurRx is not responsible for the completeness, accuracy, timeliness or omissions contained in the report, or for the results obtained from the use of the information contained in the report, which may not provide all information material to an investor’s decision whether or not to make an investment. AzurRx is not responsible for the results obtained from the use of the information contained in the report. Investors should carefully review AzurRx’s reports filed with the Securities and Exchange Commission (SEC) before deciding to invest, including AzurRx’s risk factors contained in its Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2019, and subsequent Quarterly Reports filed on Form 10-Q, and Current Reports filed on Form 8-K.